Thermo Fisher awaits regulatory nod for Life Tech acquisition

Thermo Fisher awaits monopoly commissions decisions on $13.6bn Life Tech acquisition

Thermo Fisher has applied to the EU and New Zealand’s competition commissions for approval of its acquisition of Life Technologies. 

When Thermo Fisher paid $13.6Bn (€10.1bn) to acquire Life Technologies in April this year the firm said the combination created an “unrivalled industry leader” in the life science industry. However, though the Board approved the purchase in August the company still needs regulatory clearance and the New Zealand Commerce Commission today received its application.

“[Thermo Fisher and Life Technologies] produce a wide range of products for scientific applications,” the regulator said in a statement, noting “areas of product overlap include cell culture, transplant diagnostics, protein and molecular biology.”

The Commission will make a decision by the 21st of this month, whilst a separate clearance application filed with the European Commission last month was resubmitted earlier this week to include a series of commitments to ensure the industry remains competitive as part of the watchdog’s inquiry. The provisional deadline for a decision is on November 25.

In a conference call discussing the company’s Q3 results last month (transcript here), Thermo Fisher CEO Marc Casper said in addition to the Board’s approval of the deal “the integration planning teams are right on schedule” and the firm “continues to work through the regulatory process.”

“The integration planning for Life Technologies is progressing well, and we look forward to the value this transaction will create,” he said, adding “day one planning is nearly complete.”

In 2006, the merger of Thermo Electron Corporation and Fisher Scientific International was approved by the US Federal trade Commission only when the firm agreed to divest its vacuum concentrators business, Genevac.

For the quarter, sales of the company’s Laboratory Products and Services increased 4% to $1.58bn on last year, representing almost half Thermo Fisher’s total revenue for the period.

Related News

Thermo Fisher must divest certain businesses, according to the EC

Thermo Fisher to divest HyClone cell culture biz following Life Tech approval

Siemens wins Pfier companion diagnostics deal

Siemens wins Pfizer companion diagnostics deal

HyClone units to keep Utah and Colorado HQs says GE

HyClone units to keep Utah and Colorado HQs says GE Healthcare

China antitrust agency insists Thermo Fisher cuts prices

China OKs $13bn Life Tech takeover but insists on Thermo price cuts

Life Technology acquisition coming together, with Thermo Fisher predicting February approval

Thermo Fisher: 'Life begins in February,' as it awaits FTC approval

Big Pharma biopharma buyouts boost M&A activity in Q4

Big Pharma biopharma buyouts boost M&A activity in Q4

Thermo Fisher talks Life integration and long-term synergies

Thermo Fisher talks Life integration and long-term synergies

The miniflex can dispense up to 370mL per minute.

Thermo Fisher: new pumps compatible with all bioprocessing techs

Image: iStock/designer491

Thermo Fisher bags single-use bioreactor tech partner Finesse

Thermo Fisher Scientif Speak Single Use at Interphex, New York

Thermo Fisher: Single-Use Tech's Evolution and Increased Industry Use

Thermo fishe's for pharma mol bio business in Eastern Europe

Thermo Fisher targets Eastern Europe’s pharmas with new R&D site

New DPM plant opens in Singapore

Thermo Fisher Opens First Dry Powder Media Plant in Singapore

Thermo Fisher Acquires Life Tech for $13.6B

Thermo Fisher Acquires Life Tech for $13.6B

Thermo looks to lab service unit to accelerate growth in 2012

Thermo looks to lab service unit to accelerate growth in 2012

Single use tech for biopharma: Pall and Thermo Fisher

The quest for more understanding is behind the single use boom: Pall and Thermo Fisher

Related Products

See more related products